LYNNE TAVERA: Open Payments
NPI 1952442535 · BURLINGAME, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,416 in 98 payments from 17 companies in 2025. Trend: 2023 $2,418 · 2024 $1,896 · 2025 $2,416
Food & beverage: $2,416
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 10 | $407 |
| Madrigal Pharmaceuticals | 15 | $373 |
| ABBVIE INC. | 14 | $308 |
| Janssen Biotech, Inc. | 8 | $251 |
| Aimmune Therapeutics, Inc. | 13 | $211 |
| Ardelyx, Inc. | 6 | $177 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $176 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $159 |
| Ipsen Biopharmaceuticals, Inc | 3 | $74 |
| Novo Nordisk Inc | 3 | $62 |
Products named: REZDIFFRA, TREMFYA, ZENPEP, IBSRELA, XIFAXAN, ENTYVIO, RINVOQ, IQIRVO.
Industry payments across CA — which companies pay providers there.
